SCHEMBL2275018

SCHEMBL2275018

O=C(O)c1cc(F)ccn1.[Zn]

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.59
ALDH1A1 P00352 3/20 0.59
ASPH Q12797 3/20 0.59
KDM8 Q8N371 3/20 0.59
KDM5A P29375 2/20 0.59
KDM3A Q9Y4C1 2/20 0.59
KDM6B O15054 1/20 0.59
TET3 O43151 1/20 0.59
KDM4A O75164 1/20 0.59
BBOX1 O75936 1/20 0.59
MAPT P10636 1/20 0.59
KDM5C P41229 1/20 0.59
KDM4D Q6B0I6 1/20 0.59
TET2 Q6N021 1/20 0.59
ALKBH5 Q6P6C2 1/20 0.59
KDM7A Q6ZMT4 1/20 0.59
TET1 Q8NFU7 1/20 0.59
EGLN2 Q96KS0 1/20 0.59
FTO Q9C0B1 1/20 0.59
EGLN1 Q9GZT9 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231979 0.98 KDM4E (0.61) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL29954072 0.98 KDM4E (0.61) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL3223370 0.80 KMO (0.65) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL1612977 0.79 ALDH1A1 (0.50) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL7692385 0.79 ADORA3 (0.45) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL23874595 0.79 GRM5 (0.43) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL30668214 0.79 ADORA3 (0.45) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL30004144 0.79 ALDH1A1 (0.50) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL24572141 0.79 KMO (0.62) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL30800092 0.78 KMO (0.71) KDM4EALDH1A1ASPHKDM8KDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003688-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2011-08-23 US disclosed
US-7671086-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S (DK) 2010-03-02 US disclosed
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2009-09-10 US disclosed
US-7585890-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUNPHARM A/S (DK) 2009-09-08 US disclosed
EP-2089422-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN Natimmune A/S (DK) 2009-08-19 EP disclosed
WO-2008106979-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL IMMUPHARM A/S (DK) 2008-09-12 WO disclosed
CN-100411617-C Method of treating symptons of common cold allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2008-08-20 CN disclosed
WO-2008064686-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN NATIMMUNE A/S (DK) 2008-06-05 WO disclosed
EP-1556021-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM AS (DK) 2007-12-19 EP disclosed
US-7166640-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2007-01-23 US disclosed
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S C/O NOVI A/S, NIELS JERNES VEJ 10 (DK) 2006-07-06 US disclosed
EP-1307189-B1 USE OF HYDROXYETHYLRUTOSIDES FOR TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2006-05-10 EP disclosed
CN-1717227-A Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM AS (DK) 2006-01-04 CN disclosed
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2005-11-03 US disclosed
EP-1556021-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL Immupharm A/S (DK) 2005-07-27 EP disclosed
WO-2004037237-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2004-05-06 WO disclosed
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2004-03-18 US disclosed
CN-1466454-A Method for treating symptoms of common cold, allergic rhinitis and respiratory tract related infections ���·�ķ��˾ 2004-01-07 CN disclosed
EP-1307189-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT Immupharm APS (DK) 2003-05-07 EP disclosed
WO-2002009699-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol CHIA, MAVS, C1QBP KDM4E 430/4885ALDH1A1 1674/4885ASPH 2488/4885
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KDM4E 4189/4885ALDH1A1 1900/4885ASPH 776/4885
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KDM4E 4189/4885ALDH1A1 1900/4885ASPH 776/4885
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL CHIA, MAVS, C1QBP KDM4E 430/4885ALDH1A1 1674/4885ASPH 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.